Spermbots and Their Applications in Assisted Reproduction: Current Progress and Future Perspectives
DOI: https://doi.org/10.2147/ijn.s465548
IF: 7.033
2024-05-31
International Journal of Nanomedicine
Abstract:Yixuan Zhang, 1, &ast Min Wang, 2, &ast Ting Zhang, 3 Honghua Wang, 2 Ying Chen, 1 Tao Zhou, 1 Rui Yang 1 1 Research Institute for Reproductive Medicine and Genetic Diseases, Wuxi Maternity and Child Health Care Hospital, Wuxi, 214002, People's Republic of China; 2 Center for Reproductive Medicine, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, 214002, People's Republic of China; 3 Department of Laboratory Medicine, Wuxi Maternity and Child Health Care Hospital, Jiangnan University, Wuxi, 214002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tao Zhou; Rui Yang, Email ; Sperm quality is declining dramatically during the past decades. Male infertility has been a serious health and social problem. The sperm cell driven biohybrid nanorobot opens a new era for automated and precise assisted reproduction. Therefore, it is urgent and necessary to conduct an updated review and perspective from the viewpoints of the researchers and clinicians in the field of reproductive medicine. In the present review, we first update the current classification, design, control and applications of various spermbots. Then, by a comprehensive summary of the functional features of sperm cells, the journey of sperms to the oocyte, and sperm-related dysfunctions, we provide a systematic guidance to further improve the design of spermbots. Focusing on the translation of spermbots into clinical practice, we point out that the main challenges are biocompatibility, effectiveness, and ethical issues. Considering the special requirements of assisted reproduction, we also propose the three laws for the clinical usage of spermbots: good genetics, gentle operation and no contamination. Finally, a three-step roadmap is proposed to achieve the goal of clinical translation. We believe that spermbot-based treatments can be validated and approved for in vitro clinical usage in the near future. However, multi-center and multi-disciplinary collaborations are needed to further promote the translation of spermbots into in vivo clinical applications. Keywords: assisted reproduction, biohybrid nanorobot, clinical translation, male infertility, spermbot Graphical According to the latest WHO report, infertility affects about 1 in 6 reproductive-aged couples, which has been a serious health and social burden. 1 Male factors are estimated to be responsible for 50% of infertility cases. 2 The causes of male infertility or subfertility are complex, including but not limited to genetic abnormalities, anatomical defects, erectile dysfunction, hormonal disorders, oxidative stress, and psychoactive drugs. 3 However, it is known that up to 90% of male problems will end up to low sperm count or poor sperm quality. Thus, semen analysis is the most widely used as well as the most efficient laboratory testing for the diagnosis of male infertility. The reference standard values for the main semen parameters tend to be lower in each new edition of the WHO manual for human semen analysis. 4 For example, the lower limit value of semen volume has changed from 2 mL to 1.4 mL, and the lower limit percentage of progressive sperm motility has decreased from 60% to 30%. On the other hand, the recent retrospective study and meta-analysis showed that human sperm quality is decreasing dramatically during the past decades, due to the issues of environmental exposure and unhealthy lifestyle. 5,6 The assisted reproductive technologies (ART) offer ultimate solutions for the treatment of infertility. There are already many options for male factor infertility in clinical practices. 7 Generally, the cases of sperm-related infertility can be classified into two main categories: with or without mature sperms in the seminal fluid. For the first condition, the in vitro fertilization (IVF) is usually used for oligospermia patients with low sperm count. While the intracytoplasmic sperm injection (ICSI), which directly injects a single sperm into the oocyte, is effective for asthenospermia patients with low sperm motility. If mature sperms cannot be detected in the semen, surgical approaches via epididymal or testicular sperm extraction can be used to obtain sperm cells for obstructive azoospermia patients. Finally, for the cases of non-obstructive azoospermia or testicular cancer, donor sperms from the sperm bank can be used for the subsequent procedure of intrauterine insemination (IUI). Although ART has successfully helped the birth of millions of infants to date, a large portion of cycles still fail. 8 Besides, ART procedures are usually time-consuming and expen -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology